Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| BSX | BOSTON SCIENTIFIC CORP | 2026-04-02 18:59:30 | 63.5 | 0.68 | 1.08 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSX | 0000885725 | BOSTON SCIENTIFIC CORP | US1011371077 | Y6ZDD9FP4P8JSSJMW954 | 042695240 | NYSE | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 300 BOSTON SCIENTIFIC WAY | MARLBOROUGH | MA | 01752-1234 | UNITED STATES | US | 508-683-4000 | 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA, 01752-1234 | 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA, 01752-1234 | — | Medical device | 1979-06-29 | Michael F. Mahoney | 59,000 | http://bostonscientific.com | 158,700,000,000 | 1,746,290,165 | 1,483,885,456 | Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. | 2026-04-02 15:14:33 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 158,700,000,000 | 45,600,000,000 | 40.3183 | 1,483,885,456 | 8,107,352 | 0.5494 |
| 2024 | 113,100,000,000 | 34,100,000,000 | 43.1646 | 1,475,778,104 | 8,682,477 | 0.5918 |
| 2023 | 79,000,000,000 | 25,800,000,000 | 48.4962 | 1,467,095,627 | 32,315,523 | 2.2523 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Arthur C. Butcher | Executive Vice President, Group President | 2025 | 744,822 | — | 3,447,272 | 1,012,501 | 219,667 | 6,534,719 |
| Jonathan R. Monson | Executive Vice President, Chief Financial Officer | 2025 | 591,848 | — | 1,624,898 | 840,000 | 38,453 | 6,083,679 |
| Michael F. Mahoney | President, Chairman Of The Board, Chief Executive Officer | 2025 | 1,442,603 | — | 13,608,056 | 4,002,001 | 287,799 | 23,532,050 |
| Vance R. Brown | General Counsel, Senior Vice President, Corporate Secretary | 2025 | 659,086 | — | 1,723,636 | 897,751 | 45,286 | 3,920,644 |
| Joseph M. Fitzgerald | Executive Vice President, Group President | 2025 | 892,604 | — | 4,309,282 | 1,458,001 | 45,657 | 8,042,997 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 59,000 |
| 2024 | 53,000 |
| 2023 | 48,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 20,074,000,000 | 16,747,000,000 | 14,240,000,000 |
| Cost Of Revenue | 6,221,000,000 | 5,257,000,000 | 4,345,000,000 |
| Gross Profit | 13,854,000,000 | 11,490,000,000 | 9,896,000,000 |
| Research And Development Expenses | 2,052,000,000 | 1,615,000,000 | 1,414,000,000 |
| General And Administrative Expenses | 6,887,000,000 | 5,984,000,000 | 5,190,000,000 |
| Operating Expenses | 10,241,000,000 | 8,887,000,000 | 7,553,000,000 |
| Operating Income | 3,613,000,000 | 2,603,000,000 | 2,343,000,000 |
| Net Income | 2,892,000,000 | 1,846,000,000 | 1,592,000,000 |
| Earnings Per Share Basic | 1.96 | 1.26 | 1.08 |
| Earnings Per Share Diluted | 1.94 | 1.25 | 1.07 |
| Weighted Average Shares Outstanding Basic | 1,480,400,000 | 1,471,500,000 | 1,453,000,000 |
| Weighted Average Shares Outstanding Diluted | 1,494,500,000 | 1,485,900,000 | 1,463,500,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,965,000,000 | 414,000,000 | 865,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | 2,943,000,000 | 2,810,000,000 | 2,484,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | 831,000,000 | 621,000,000 |
| Total Assets Current | 8,794,000,000 | 6,920,000,000 | 6,514,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 4,036,000,000 | 3,294,000,000 | 2,859,000,000 |
| Other Assets Non Current | 1,866,000,000 | 1,754,000,000 | 1,531,000,000 |
| Total Assets Non Current | 29,802,000,000 | 27,516,000,000 | 23,688,000,000 |
| Total Assets | 43,673,000,000 | 39,395,000,000 | 35,136,000,000 |
| Accounts Payable | 1,144,000,000 | 960,000,000 | 942,000,000 |
| Deferred Revenue | 313,000,000 | 306,000,000 | 266,000,000 |
| Short Term Debt | 299,000,000 | 1,778,000,000 | 531,000,000 |
| Other Liabilities Current | 795,000,000 | 887,000,000 | 814,000,000 |
| Total Liabilities Current | 5,439,000,000 | 6,399,000,000 | 4,933,000,000 |
| Long Term Debt | 11,137,000,000 | 8,968,000,000 | 8,571,000,000 |
| Other Liabilities Non Current | 2,405,000,000 | 1,870,000,000 | 1,967,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 17,000,000 | 17,000,000 | 17,000,000 |
| Retained Earnings | 5,571,000,000 | 2,673,000,000 | 819,000,000 |
| Accumulated Other Comprehensive Income | -610,000,000 | 275,000,000 | 49,000,000 |
| Total Shareholders Equity | 24,233,000,000 | 21,770,000,000 | 19,282,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,368,000,000 | 1,269,000,000 | 1,196,000,000 |
| Share Based Compensation Expense | 299,000,000 | 266,000,000 | 233,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 269,000,000 | 351,000,000 | 238,000,000 |
| Change In Inventories | 188,000,000 | 228,000,000 | 660,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 85,000,000 | 126,000,000 | -10,000,000 |
| Change In Accounts Payable | 296,000,000 | 243,000,000 | 118,000,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 4,534,000,000 | 3,435,000,000 | 2,503,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 876,000,000 | 790,000,000 | 711,000,000 |
| Acquisition Of Business | 1,593,000,000 | 4,640,000,000 | 1,811,000,000 |
| Other Investing Activities | -84,000,000 | -20,000,000 | -30,000,000 |
| Cash From Investing Activities | -2,640,000,000 | -5,687,000,000 | -2,574,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | 0 | 28,000,000 |
| Issuance Of Common Stock | 282,000,000 | 230,000,000 | 182,000,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 1,558,000,000 | 2,145,000,000 | 0 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 7,000,000 | — | — |
| Cash From Financing Activities | -395,000,000 | 1,814,000,000 | 5,000,000 |
| Change In Cash | 1,541,000,000 | -450,000,000 | -70,000,000 |
| Cash At End Of Period | 1,965,000,000 | 414,000,000 | 865,000,000 |
| Income Taxes Paid | 561,000,000 | 656,000,000 | 512,000,000 |
| Interest Paid | 319,000,000 | 250,000,000 | 259,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 1.96 | 1.26 | 1.08 |
| Price To Earnings Ratio | 48.648 | 70.8889 | 53.5278 |
| Earnings Growth Rate | 55.5556 | 16.6667 | 140 |
| Price Earnings To Growth Ratio | 0.8757 | 4.2533 | 0.3823 |
| Book Value Per Share | 25.8268 | 22.4234 | 20.7866 |
| Price To Book Ratio | 3.6919 | 3.9833 | 2.7811 |
| Ebitda | 5,170,000,000 | 4,076,000,000 | 3,565,000,000 |
| Enterprise Value | 150,627,140,000 | 141,766,380,000 | 92,234,930,000 |
| Dividend Yield | — | 0 | 0.0003 |
| Dividend Payout Ratio | — | 0 | 0.0176 |
| Debt To Equity Ratio | 0.4719 | 0.4936 | 0.472 |
| Capital Expenditures | 2,110,000,000 | 1,704,000,000 | 1,609,000,000 |
| Free Cash Flow | 2,424,000,000 | 1,731,000,000 | 894,000,000 |
| Return On Equity | 0.1193 | 0.0848 | 0.0826 |
| One Year Beta | 0.682 | 0.5242 | 0.5345 |
| Three Year Beta | 0.6092 | 0.68 | 0.7472 |
| Five Year Beta | 0.7055 | 0.8839 | 0.9258 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Smith Cathy R | Director | 2026-03-02 | 556 | A | 556 |
| Smith Cathy R | Director | 2026-03-02 | 323 | A | 879 |
| Weber Christophe Pierre | Director | 2026-03-02 | 556 | A | 556 |
| Weber Christophe Pierre | Director | 2026-03-02 | 323 | A | 879 |
| Morano Susan E | Director | 2026-03-02 | 24 | A | 6,663 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Markwayne Mullin | Senator | 2026-01-16 | Purchase | 2025-12-29 | Joint | $15,001 - $50,000 |
| John Boozman | Senator | 2026-01-13 | Sale (Partial) | 2025-12-17 | Joint | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2023-11-01 | Purchase | 2023-10-03 | Joint | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2023-10-12 | Purchase | 2023-09-13 | Joint | $15,001 - $50,000 |
| Robert P Corker, Jr. | Senator | 2015-12-11 | Sale (Full) | 2014-05-20 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2026-03-09 | CA31 | Purchase | 2026-02-10 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2026-02-13 | CA31 | Purchase | 2026-01-30 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2026-01-12 | CA31 | Sale (Partial) | 2025-12-24 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-12-15 | CA31 | Purchase | 2025-11-18 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| ADIRONDACK TRUST CO | 2026-03-31 | 33,633 | 536 | 62.7481 |
| Hickory Point Bank & Trust | 2026-03-31 | 9,413 | 150 | 62.7533 |
| Coastline Trust Co | 2026-03-31 | 31,187 | 497 | 62.7505 |
| Global Wealth Strategies & Associates | 2026-03-31 | 13,742 | 219 | 62.7489 |
| Ares Financial Consulting, LLC | 2026-03-31 | 27,280 | 440 | 62 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily S&P 500(R) Bull 2X ETF | SPUU | 5,475 | 512,076.75 | 0.2201 |
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily S&P 500(R) Bull 3X ETF | SPXL | 103,186 | 9,650,986.58 | 0.1692 |
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily Healthcare Bull 3X ETF | CURE | 33,940 | 3,174,408.2 | 1.9248 |
| Direxion Shares ETF Trust | 2026-01-31 | Direxion HCM Tactical Enhanced US ETF | HCMT | 11,808 | 1,104,402.24 | 0.1892 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco S&P 500 Equal Weight ETF | RSP | 1,718,823 | 160,761,515.19 | 0.1967 |